Evidence map›Paper›PMID 37837521›Full record

ArticlePharmacological reports : PR2023

Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models.

Jeferson Gustavo Henn, Matheus Bernardes Ferro, Gabriel Antonio Lopes Alves, Flávia Pires Peña, João Vitor Raupp de Oliveira, Bárbara Müller de Souza, Leonardo Fonseca da Silva, Victória Rapack Jacinto Silva, Ana Carolina Silva Pinheiro, Luiza Steffens Reinhardt and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Jeferson Gustavo HennLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Matheus Bernardes FerroLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Gabriel Antonio Lopes AlvesLaboratório de Farmacociências, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Flávia Pires PeñaLaboratório de Farmacociências, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
João Vitor Raupp de OliveiraLaboratório de Farmacociências, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Bárbara Müller de SouzaDepartamento de Química Inorgânica, Universidade Federal do Rio Grande do Sul, 9500 Bento Gonçalves Avenue, Porto Alegre, Rio Grande do Sul, 91501-970, Brazil.
Leonardo Fonseca da SilvaDepartamento de Química Inorgânica, Universidade Federal do Rio Grande do Sul, 9500 Bento Gonçalves Avenue, Porto Alegre, Rio Grande do Sul, 91501-970, Brazil.
Victória Rapack Jacinto SilvaLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Ana Carolina Silva PinheiroLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Luiza Steffens ReinhardtLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Ana Moira MorásLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Michael NugentMaterials Research Institute, Technological University of the Shannon: Midlands Midwest, Athlone, Co. Westmeath, N37HD68, Ireland.
Ricardo Gomes da RosaDepartamento de Química Inorgânica, Universidade Federal do Rio Grande do Sul, 9500 Bento Gonçalves Avenue, Porto Alegre, Rio Grande do Sul, 91501-970, Brazil.
Tanira Alessandra Silveira AguirreLaboratório de Farmacociências, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil.
Dinara Jaqueline MouraLaboratório de Genética Toxicológica, Universidade Federal de Ciências da Saúde de Porto Alegre, 245 Sarmento Leite Street, Lab. 714, Porto Alegre, Rio Grande do Sul, 90050-170, Brazil. dinaram@ufcspa.edu.br.ORCID http://orcid.org/0000-0002-7232-5002
Universidade Federal de Ciências da Saúde de Porto Alegre · BRUniversidade Federal do Rio Grande do Sul · BRTechnological University of the Shannon: Midlands Midwest

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma is a severe brain tumor that requires aggressive treatment involving surgery, radiotherapy, and chemotherapy, offering a survival rate of only 15 months. Fortunately, recent nanotechnology progress has enabled novel approaches and, alongside ferrocenes' unique properties of cytotoxicity, sensitization, and interaction with reactive oxygen species, have brought new possibilities to complement chemotherapy in nanocarrier systems, enhancing treatment results.

methodsIn this work, we developed and characterized a temozolomide-loaded nanoemulsion and evaluated its cytotoxic potential in combination with ferrocene in the temozolomide-resistant T98G and temozolomide-sensitive U87 cell lines. The effects of the treatments were assessed through acute assays of cell viability, cell death, mitochondrial alterations, and a treatment protocol simulation based on different two-cycle regimens.

resultsTemozolomide nanoemulsion showed a z-average diameter of 173.37 ± 0.86 nm and a zeta potential of - 6.53 ± 1.13 mV. Physicochemical characterization revealed that temozolomide is probably associated with nanoemulsion droplets instead of being entrapped within the nanostructure, allowing a rapid drug release. In combination with ferrocene, temozolomide nanoemulsion reduced glioblastoma cell viability in both acute and two-cycle regimen assays. The combined treatment approach also reversed T98G's temozolomide-resistant profile by altering the mitochondrial membrane potential of the cells, thus increasing reactive oxygen species generation, and ultimately inducing cell death.

conclusionsAltogether, our results indicate that using nanoemulsion containing temozolomide in combination with ferrocene is an effective approach to improve glioblastoma therapy outcomes.

Indexed as

Brain NeoplasmsGlioblastomaCell Line, TumorFerrous CompoundsHumansMetallocenesReactive Oxygen SpeciesTemozolomideferroceneFerrous CompoundsMetallocenesReactive Oxygen SpeciesTemozolomideDrug delivery systemFerroceneGlioblastomaNanoemulsionTemozolomide

Identifiers

PMID37837521
OpenAlexW4387639359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.